Ikena Oncology Inc
(NAS:IKNA)
$
1.57
0.04 (2.61%)
Market Cap: 75.77 Mil
Enterprise Value: -55.80 Mil
PE Ratio: 0
PB Ratio: 0.56
GF Score: 33/100 Ikena Oncology Inc at Credit Suisse Healthcare Conference (Virtual) Transcript
Nov 11, 2021 / 08:30PM GMT
Release Date Price:
$16.26
(-2.81%)
Judah C. Frommer;dit Suisse AG
CrÃ;Research Division - Senior Analyst
© -
Hi and welcome to the afternoon session of the 2021 Credit Suisse Healthcare Conference. I'm Judah Frommer. I cover biotech here at CS. With us for this session, we have Ikena. We're thrilled to have a good chunk of the team here, Mark, Sergio and Doug. I'll just let the audience know that if you do have questions for the team, you can certainly e-mail those to me at [email protected]. But with that intro, maybe we'll all hop right into our Q&A list, which is reasonably lengthy.
Questions & Answers
Judah C. Frommer;dit Suisse AG
CrÃ;Research Division - Senior Analyst
© -
So Mark, I thought we could start with a brief history lesson on Ikena. How from a high level your approach across targeted oncology and tumor microenvironment is somewhat differentiated versus peers.
Mark Manfredi
Ikena Oncology, Inc. - President. CEO & Director
Sure. Thanks for having us,
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot